Reported Reactions

Drugs

Generic name

Vitamins: adverse event reports filed with FDA

1,582 reports list it as a suspect or interacting product, 2004–2026. Also reported as Vitamins Nos, Vitamins /90003601/, Vitamins /00067501/.

1,582
reports as suspect product
0% of all reports · about 71 a year
159
reports, 12 months to June 2026
202 in the 12 months before
77.1%
marked serious by the reporter
57.4% across all reports
10.6%
record death among outcomes, as reported
167 reports · not verified by FDA

1,582 adverse event reports received by FDA list vitamins, a generic name as a suspect or interacting product, from April 2004 to June 2026. A further 92,474 reports list it only as a concomitant medication, and those are not counted in the figures on this page.

In the 12 months to June 2026, 159 reports listed it, down 21% from 202 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 71 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.

Reporters most often recorded drug ineffective (16.2%), off label use (14.2%) and pain (9.7%). A report can list several reactions, so shares add to more than 100%; 683 different terms appear across these reports. Drug ineffective is recorded in 16.2% of these reports, against 6.3% of all reports in the database.

77.1% of the reports are marked serious by the reporter; 10.6% record death among the outcomes and 33% record hospitalisation, as reported. 38.1% of the reports came from other health professionals, and the largest patient age group is 18 to 44 (19.1%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

01836Jul 2021: 14Aug 2021: 13Sep 2021: 14Oct 2021: 16Nov 2021: 16Dec 2021: 302022Jan 2022: 18Feb 2022: 21Mar 2022: 13Apr 2022: 19May 2022: 18Jun 2022: 10Jul 2022: 13Aug 2022: 19Sep 2022: 11Oct 2022: 14Nov 2022: 20Dec 2022: 222023Jan 2023: 17Feb 2023: 18Mar 2023: 23Apr 2023: 33May 2023: 36Jun 2023: 36Jul 2023: 19Aug 2023: 31Sep 2023: 13Oct 2023: 29Nov 2023: 11Dec 2023: 212024Jan 2024: 26Feb 2024: 23Mar 2024: 16Apr 2024: 23May 2024: 31Jun 2024: 14Jul 2024: 12Aug 2024: 16Sep 2024: 17Oct 2024: 17Nov 2024: 15Dec 2024: 102025Jan 2025: 26Feb 2025: 21Mar 2025: 29Apr 2025: 14May 2025: 11Jun 2025: 14Jul 2025: 14Aug 2025: 10Sep 2025: 18Oct 2025: 13Nov 2025: 12Dec 2025: 122026Jan 2026: 16Feb 2026: 13Mar 2026: 13Apr 2026: 12May 2026: 5Jun 2026: 21

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

01442872004: 320042005: 92006: 72007: 1020072008: 122009: 102010: 3020102011: 182012: 332013: 4020132014: 402015: 332016: 2120162017: 152018: 292019: 7420192020: 642021: 1552022: 19820222023: 2872024: 2202025: 19420252026: 80

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Vitamins reports recording the termall reports in the database

  1. Drug ineffectivethe medicine did not work as expected16.2%257
  2. Off label useused for a purpose or in a way not on the label14.2%224
  3. Painpain, site not specified9.7%153
  4. Product use in unapproved indicationused for a purpose not on the label8.6%136
  5. Nauseafeeling sick8.5%135
  6. Vomitingbeing sick7.8%123
  7. Headachehead pain6.4%102
  8. Dyspnoeashortness of breath5.9%94
  9. Maternal exposure during pregnancythe mother took the medicine during pregnancy5.8%91
  10. Abdominal pain upperupper stomach pain5.7%90
  11. Drug intolerancethe medicine was not tolerated5.6%89
  12. Memory impairmentmemory problems5.5%87
  13. Diarrhoealoose or frequent stools5.2%82
  14. Fatiguetiredness5.2%82
  15. Arthralgiajoint pain5.1%81
  16. Paraesthesiatingling or pins and needles5.1%81
  17. Pyrexiafever5.1%81
  18. Dizzinesslight-headedness or unsteadiness5%79
  19. Rashskin rash4.9%77
  20. Weight decreasedweight loss4.9%77
  21. Macular degenerationa disease of the central retina4.7%74
  22. Foetal exposure during pregnancythe unborn baby was exposed to the medicine4.4%70
  23. Hypoaesthesianumbness4.4%70
  24. Sleep disordera sleep problem4.4%70
  25. Condition aggravatedthe condition being treated got worse4.4%69
  26. Malaisegeneral feeling of being unwell4.3%68
  27. Infusion related reactiona reaction during or soon after an infusion4.2%67
  28. Migrainemigraine4.2%67

Top 30 of 683 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Death10.6%167
Life-threatening9.8%155
Hospitalisation (initial or prolonged)33%522
Disability7.6%120
Congenital anomaly4.4%69
Other serious63%997
Not serious22.9%362

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Patient age

Under 22.1%33
2 to 112.2%35
12 to 171.6%25
18 to 4419.1%302
45 to 6417.3%274
65 to 7410.9%173
75 and over10.8%171
Age not given36%569

Patient sex

Female60.7%961
Male26.1%413
Not given13.1%208

Who reported

Physician19.6%310
Pharmacist4.9%77
Other health professional38.1%603
Lawyer0.2%3
Consumer or non-health professional33.8%534
Not given3.5%55

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 46.6% of reports give the United States as the country of the event or reporter.

Reason for use recorded

Indication as recorded (MedDRA)ReportsShare
Parenteral nutrition553.5%
Vitamin supplementation523.3%
Psoriasis442.8%
Nutritional supplementation322%
Supplementation therapy120.8%
Psoriatic arthropathy110.7%

The indication field is filled in by the reporter and is often blank; shares are of all 1,582 reports.

In context

MeasureVitaminsAll reports
Reports as suspect product1,58220,646,523
Share of that pool—0%
Reports, latest 12 months1591,332,454
Marked serious77.1%57.4%
Death recorded among outcomes, per 1,000 reports10691
Hospitalisation recorded, per 1,000 reports330213
Consumer-filed share33.8%45.8%
Top term, share of reportsDrug ineffective 16.2%6.3%

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Questions about Vitamins reports

How many adverse event reports has FDA received for Vitamins?

1,582 reports list Vitamins as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 159 of them arrived in the latest 12 months. Another 92,474 list it only as a concomitant medication.

What reactions are recorded in Vitamins reports?

drug ineffective (16.2%), off label use (14.2%), pain (9.7%), product use in unapproved indication (8.6%) and nausea (8.5%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Vitamins was responsible.

How serious are the reports?

77.1% are marked serious by the reporter. Among the outcomes recorded, 10.6% of reports include death and 33% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.

Who files these reports?

other health professional (38.1%), consumer or non-health professional (33.8%) and physician (19.6%). Most reports reach FDA through the manufacturer, which must forward reports it receives.

Are reports for Vitamins rising?

159 reports in the 12 months to June 2026, down 21% from 202 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.

Do these reports show that Vitamins was responsible for these reactions?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.

Is this a list of the side effects of Vitamins?

No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.

How do I report an adverse event?

Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Vitamins as a suspect or interacting product; reports listing it only as a concomitant medication (92,474) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.